These antibodies include BM-986016, REGN3767, and TSR033.33 The first anti-LAG-3 antibody relatlimab, BMS-986016, was developed in 2013 and is currently undergoing evaluation in more than 12 phase I and II clinical trials in hematological and solid tumors.33,34 The first report on efficacy of relatlimab in melanoma was introduced through a phase I/II clinical trial (NCT01968609). Here, LAG3 is linked to melanoma.